{"id":"acei-arb-finerenone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Acute kidney injury"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ACE inhibitors and ARBs reduce angiotensin II-mediated vasoconstriction and aldosterone release, lowering blood pressure and proteinuria. Finerenone selectively antagonizes the mineralocorticoid receptor in the kidney and cardiovascular tissues, providing additional renoprotection and cardioprotection independent of blood pressure reduction. Together, they address multiple pathways in the renin-angiotensin-aldosterone system (RAAS) to slow chronic kidney disease progression.","oneSentence":"This combination therapy blocks angiotensin II signaling via ACE inhibitors or ARBs while finerenone acts as a non-steroidal mineralocorticoid receptor antagonist to reduce kidney and cardiovascular injury.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:26:04.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic kidney disease with hypertension"},{"name":"Diabetic kidney disease"}]},"trialDetails":[{"nctId":"NCT05457283","phase":"PHASE3","title":"A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-11-08","conditions":"Chronic Kidney Disease, Proteinuria, Children","enrollment":100},{"nctId":"NCT05196035","phase":"PHASE3","title":"A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-03-28","conditions":"Chronic Kidney Disease, Proteinuria","enrollment":219},{"nctId":"NCT07356388","phase":"PHASE3","title":"FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan","status":"ACTIVE_NOT_RECRUITING","sponsor":"kewen Chen,MD","startDate":"2025-01-30","conditions":"Kidney Transplantation Recipients, Proteinuria Patients","enrollment":54},{"nctId":"NCT07348718","phase":"","title":"Rubix LS Diabetic Kidney Disease (DKD) Registry Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rubix LS","startDate":"2025-12-15","conditions":"Diabetic Kidney Disease (DKD)","enrollment":2000},{"nctId":"NCT07315191","phase":"PHASE4","title":"Finerenone Therapy for Pediatric HSPN With Mild Proteinuria","status":"RECRUITING","sponsor":"Capital Institute of Pediatrics, China","startDate":"2025-06-13","conditions":"Henoch Schönlein Purpura Nephritis","enrollment":116},{"nctId":"NCT02378805","phase":"","title":"Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome","status":"RECRUITING","sponsor":"University Hospital Goettingen","startDate":"1995-07","conditions":"Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease","enrollment":800},{"nctId":"NCT05897372","phase":"PHASE2","title":"Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study","status":"TERMINATED","sponsor":"Iain Bressendorff","startDate":"2023-08-01","conditions":"Diabetic Kidney Disease","enrollment":1},{"nctId":"NCT06573411","phase":"PHASE4","title":"Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-09-30","conditions":"Primary Membranous Nephropathy","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ACEI / ARB+finerenone","genericName":"ACEI / ARB+finerenone","companyName":"Capital Institute of Pediatrics, China","companyId":"capital-institute-of-pediatrics-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy blocks angiotensin II signaling via ACE inhibitors or ARBs while finerenone acts as a non-steroidal mineralocorticoid receptor antagonist to reduce kidney and cardiovascular injury. Used for Chronic kidney disease with hypertension, Diabetic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}